DE69516847T2 - Chlorpyrimidine als zwischenprodukte - Google Patents

Chlorpyrimidine als zwischenprodukte

Info

Publication number
DE69516847T2
DE69516847T2 DE69516847T DE69516847T DE69516847T2 DE 69516847 T2 DE69516847 T2 DE 69516847T2 DE 69516847 T DE69516847 T DE 69516847T DE 69516847 T DE69516847 T DE 69516847T DE 69516847 T2 DE69516847 T2 DE 69516847T2
Authority
DE
Germany
Prior art keywords
chlorpyrimidine
intermediate products
processes
aminopurines
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69516847T
Other languages
English (en)
Other versions
DE69516847D1 (de
Inventor
Mary Daluge
Tolar Martin
Joanne Fugett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69516847(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69516847D1 publication Critical patent/DE69516847D1/de
Publication of DE69516847T2 publication Critical patent/DE69516847T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Liquid Crystal Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE69516847T 1994-02-04 1995-02-03 Chlorpyrimidine als zwischenprodukte Expired - Lifetime DE69516847T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402161A GB9402161D0 (en) 1994-02-04 1994-02-04 Chloropyrimidine intermediates
PCT/GB1995/000225 WO1995021161A1 (en) 1994-02-04 1995-02-03 Chloropyrimide intermediates

Publications (2)

Publication Number Publication Date
DE69516847D1 DE69516847D1 (de) 2000-06-15
DE69516847T2 true DE69516847T2 (de) 2000-10-26

Family

ID=10749873

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69516847T Expired - Lifetime DE69516847T2 (de) 1994-02-04 1995-02-03 Chlorpyrimidine als zwischenprodukte

Country Status (28)

Country Link
US (8) US6448403B1 (de)
EP (1) EP0741710B1 (de)
JP (1) JP3670012B2 (de)
KR (1) KR100355983B1 (de)
CN (2) CN1161343C (de)
AT (1) ATE192742T1 (de)
AU (1) AU690203B2 (de)
BR (1) BR9506667A (de)
DE (1) DE69516847T2 (de)
DK (1) DK0741710T3 (de)
ES (1) ES2148486T3 (de)
FI (1) FI112477B (de)
GB (1) GB9402161D0 (de)
GR (1) GR3033850T3 (de)
HK (1) HK1004087A1 (de)
HU (1) HU223096B1 (de)
IL (1) IL112539A (de)
MX (1) MX9603091A (de)
MY (1) MY113775A (de)
NO (1) NO310819B1 (de)
NZ (1) NZ278948A (de)
PL (1) PL183885B1 (de)
PT (1) PT741710E (de)
RU (1) RU2140913C1 (de)
SG (1) SG47918A1 (de)
TW (1) TW390877B (de)
WO (1) WO1995021161A1 (de)
ZA (1) ZA95884B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation
SK284810B6 (sk) 1997-05-13 2005-12-01 Lonza Ag Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purín-9-yl)-2-cyklopentén-1-metanolu
GB9721780D0 (en) * 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
EP1032573A1 (de) * 1997-11-12 2000-09-06 Glaxo Group Limited Verfahren zur herstellung von einem chiralen nukleoside-analogon
SK284594B6 (sk) 1997-11-27 2005-07-01 Lonza Ag Spôsob výroby derivátov aminoalkoholov a ich soli
ATE252087T1 (de) * 1998-12-21 2003-11-15 Lonza Ag Verfahren zur herstellung von 2,5-diamino-4,6- dihalogenpyrimidinen
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
AU2002343604C1 (en) * 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
KR100573859B1 (ko) * 2002-07-15 2006-04-25 경동제약 주식회사 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의제조방법
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
CA2522573A1 (en) * 2003-04-30 2004-11-18 Teva Pharmaceutical Industries Ltd. Process for the preparation of famciclovir
JPWO2004103979A1 (ja) * 2003-05-26 2006-07-20 住友化学株式会社 Ｎ−（２−アミノ−４，６−ジクロロピリミジン−５−イル）ホルムアミドの製造方法
KR100573860B1 (ko) * 2003-06-13 2006-04-25 경동제약 주식회사 2-아미노-9-(2-치환에틸)푸린을 이용한 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의 제조방법
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
US20050143400A1 (en) * 2003-09-04 2005-06-30 Genny Shamai Process for preparing famciclovir
GB0320738D0 (en) * 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
DE102004002055A1 (de) * 2004-01-15 2005-08-11 Degussa Ag Verfahren zur Herstellung von 2-Amino-4,6-dichlor-5-formamidopyrimidin
EA012799B1 (ru) * 2004-08-16 2009-12-30 Кварк Фармасьютикалс, Инк. Терапевтические применения ингибиторов rtp801
WO2006105372A2 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
GB2426247A (en) 2005-05-20 2006-11-22 Arrow Int Ltd Methods of preparing purine derivatives such as famciclovir
EP1937258A2 (de) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Antitumorale verfahren mit multi-arzneiresistenz-unabhägnigen synthetischen hsp90-hemmern
EP1857458A1 (de) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Verfahren zur Herstellung von Abacavir
CN100465174C (zh) * 2006-06-13 2009-03-04 中国科学院上海有机化学研究所 制备光学纯阿巴卡韦的方法
WO2008072074A1 (en) * 2006-12-11 2008-06-19 Aurobindo Pharma Limited An improved process for the preparation of purine derivative
EP1939196A1 (de) 2006-12-21 2008-07-02 Esteve Quimica, S.A. Abacavir-Herstellungsprozess
EP2170840A1 (de) * 2007-06-21 2010-04-07 Aurobindo Pharma Ltd Verbessertes verfahren zur herstellung eines purinderivats
EP2085397A1 (de) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
TR201807704T4 (tr) 2010-01-27 2018-06-21 Viiv Healthcare Co Anti-viral tedavi.
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物
CN104672239A (zh) * 2013-11-26 2015-06-03 上海迪赛诺化学制药有限公司 一种采用一锅法制备阿巴卡韦式v中间体的工艺
CN109456329B (zh) * 2018-11-19 2021-03-09 迪嘉药业集团有限公司 一种泛昔洛韦的制备方法
CN113292507B (zh) * 2021-06-25 2022-07-19 潍坊奥通药业有限公司 一种2-氨基-6-氯鸟嘌呤及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
DE3582399D1 (de) 1984-09-20 1991-05-08 Beecham Group Plc Purin-derivate und ihre pharmazeutische verwendung.
US4965270A (en) 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
GB8724765D0 (en) 1987-10-22 1987-11-25 Beecham Group Plc Process
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4916224A (en) 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB2243609B (en) * 1988-01-20 1992-03-11 Univ Minnesota Dideoxydidehydrocarbocyclic pyrimidines
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB8916698D0 (en) 1989-07-21 1989-09-06 Beecham Group Plc Novel process
GB8918827D0 (en) 1989-08-17 1989-09-27 Beecham Group Plc Novel compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
CZ287049B6 (cs) * 1992-01-22 2000-08-16 Lonza A. G. N-5-chráněné 2,5-diamino-4,6-dichlorpyrimidiny a způsob jejich přípravy
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation

Also Published As

Publication number Publication date
JP3670012B2 (ja) 2005-07-13
US6552193B1 (en) 2003-04-22
US6087501A (en) 2000-07-11
JPH09508412A (ja) 1997-08-26
US20020173649A1 (en) 2002-11-21
BR9506667A (pt) 1997-09-16
US6448403B1 (en) 2002-09-10
US6870053B2 (en) 2005-03-22
KR100355983B1 (ko) 2002-12-28
US20030187263A1 (en) 2003-10-02
ATE192742T1 (de) 2000-05-15
TW390877B (en) 2000-05-21
ES2148486T3 (es) 2000-10-16
US5917042A (en) 1999-06-29
MX9603091A (es) 1998-01-31
MY113775A (en) 2002-05-31
GR3033850T3 (en) 2000-10-31
RU2140913C1 (ru) 1999-11-10
PL183885B1 (pl) 2002-07-31
SG47918A1 (en) 1998-04-17
HU9602114D0 (en) 1996-09-30
HU223096B1 (hu) 2004-03-29
WO1995021161A1 (en) 1995-08-10
AU1543895A (en) 1995-08-21
HK1004087A1 (en) 1998-11-13
EP0741710A1 (de) 1996-11-13
FI963070A (fi) 1996-08-02
NO963239D0 (no) 1996-08-02
CN1105109C (zh) 2003-04-09
NZ278948A (en) 1998-01-26
NO310819B1 (no) 2001-09-03
NO963239L (no) 1996-10-02
FI963070A0 (fi) 1996-08-02
PT741710E (pt) 2000-09-29
HUT75300A (en) 1997-05-28
ZA95884B (en) 1996-08-05
CN1139924A (zh) 1997-01-08
FI112477B (fi) 2003-12-15
DE69516847D1 (de) 2000-06-15
CN1161343C (zh) 2004-08-11
US6555687B1 (en) 2003-04-29
GB9402161D0 (en) 1994-03-30
IL112539A0 (en) 1995-05-26
PL315713A1 (en) 1996-11-25
US5917041A (en) 1999-06-29
AU690203B2 (en) 1998-04-23
CN1388123A (zh) 2003-01-01
DK0741710T3 (da) 2000-08-14
IL112539A (en) 2000-08-31
EP0741710B1 (de) 2000-05-10

Similar Documents

Publication Publication Date Title
DE69516847D1 (de) Chlorpyrimidine als zwischenprodukte
ID23374A (id) Halogenopirimidin
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
AU6722498A (en) Disubstituted biphenyloxazolines
DK1051404T3 (da) Substituerede phenyluraciler med herbicid virkning
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
NO982151L (no) Hemoregulatoriske forbindelser
NO960849L (no) Difluorstaton-antivirale analoger
CA2182105A1 (en) Chloropyrimide intermediates

Legal Events

Date Code Title Description
8364 No opposition during term of opposition